Article Text

Download PDFPDF

S05.2 Risk of COVID-19 induced systemic lupus erythematosus flare: analysis of the AP-HP clinical data warehouse
  1. A Mageau1,
  2. T Papo2,
  3. J Timsit3 and
  4. K Sacre2
  1. 1Inserm UMR 1137 IAME and1149 CRI, service de médecine interne, hôpital Bichat, AP-HP ~ Paris ~ France
  2. 2Inserm UMR 1149 CRI, Service de médecine interne, hôpital Bichat ~ Paris ~ France
  3. 3Inserm UMR 1137 IAME, Service de médecine intensive réanimation, hôpital Bichat, AP-HP ~ Paris ~ France


Purpose Because of the involvement of type 1 interferon (IFN-1) in the pathophysiology of both systemic lupus erythematosus (SLE) and COVID-19 immune response, a risk of post COVID-19 SLE flare could be hypothesized. Our objectives were to assess this risk and to look for factors associated with a post-COVID-19 SLE flare.

Methods We conducted a retrospective cohort study using the Assistance Publique - Hôpitaux de Paris (AP-HP) Clinical Data Warehouse which collects all the medical data produced in the 39 AP-HP facilities in Paris area. We included every adult patient with a history of SLE (defined by a ‘M32’ ICD-10 diagnosis code) and an hospital stay with a first episode of COVID-19 diagnosis (defined by a ‘U07.1’ ICD-10 code) between March 2020 and February 2022. All the medical records were individually reviewed to retrieve demographics, SLE characteristics, COVID-19-episode characteristics, and vaccination status. We look for clinically defined SLE flares during the follow-up period. Features associated with post COVID-19 SLE flares were analysed by using univariable and multivariable logistic regression procedures.

Results Among the 4,533 SLE patients followed in AP-HP, 128 (2.8%) had an hospital stay with a COVID-19 diagnosis during the period of interest. After reviewing all the individual records, we excluded 38 patients who did not meet the inclusion criteria. Accordingly, there were 90 patients included in the analysis; 84 (93.3%) were female with a median [IQR] age of 54.6 [40.8–68.3] years. The median time between SLE diagnosis and the COVID-19 episode was 13.5 [5.6–22.8] years. Seventy-three (81.1%) patients did not receive any dose of anti-Sars-Cov2 vaccine before the COVID-19 episode and 9 (10%) died directly from COVID-19. We observed 14 (15.5%) post-COVID-19 SLE flares, 6 (42.9%) of them occurred in the same hospital stay. The median time between the beginning of the COVID-19 episode and the SLE flare was 60 [20.5–117.5] days. Six (42.9%) of these flares involved the kidneys with 3 (21.4%) class III or IV glomerulonephritis. We did not observe any significant difference in the characteristics of patient who experienced a flare compared to the others. Interestingly, there were no difference in the proportion of patients vaccinated between the two groups: 10/14 (76.9) in the flare group versus 62/74 (83.8%) in the group with no flare (p=0.83).

Abstract S05.2 Table 1

Conclusions Autoimmune flares seem to be frequent after COVID-19 infection among SLE population. We did not identify any risk factor associated with a risk of post-COVID-19 SLE flare.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.